MESO

Mesoblast Limited

Fundamental data last updated:November 19, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

AU

Next Earnings Date

03/04/2027

Business Summary

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.

 


VALUATION

P/E

-29.55

Market Cap ($M USD)

$1.70B

Forward P/E

4.49

PEG

0.46

PRICE TO SALES

13.86

PRICE TO BOOK

2.99

EV / EBITDA

-39.97

5-Year Average P/E

Free Cash Flow Yield

-1.88%

DCF Value

$-26.18

Graham Number

N/A

Price to FCF

-53.33

EV to FCF

-55.84

Earnings Yield

-3.38%

FCF Yield

-1.88%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.44

Next Year EPS Growth Estimate

-$0.16

Next Year Revenue Growth Estimate

$196.10M

Return on Equity (ROE)

-10.06%

FREE CASH FLOW

Operating Margin

-96.11%

Debt-to-Equity

0.22

Piotroski F-Score

3

Altman Z-Score

3.17

Return on Invested Capital (ROIC)

-16.74%

Current Ratio

2.43

Quick Ratio

2.09

Net Debt to EBITDA

-1.79

Interest Coverage

0.00

Gross Profit margin

78.30%

FCF PER SHARE

$-0.25

REVENUE PER SHARE

$0.95

Gainseekers Quantitative Analysis

Summary

MESO Mesoblast Limited’s valuation is a paradox. Despite a Forward P/E of 4.49 suggesting potential undervaluation, the stock’s DCF value is deeply negative, indicating market skepticism about future cash flows. The Altman Z-score of 3.61 implies financial stability, yet the negative earnings yield and ROIC highlight profitability challenges. The market seems to be pricing in significant growth expectations, but the negative Price to FCF and EV to EBITDA ratios raise red flags about current operational efficiency. This stock is a speculative play, hinging on future performance rather than present fundamentals.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Mesoblast is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with technological shifts, potentially enhancing R&D efficiency. However, the company's ability to capitalize on these opportunities will depend on its strategic execution and adaptability.

The Bull Case

For the value or GARP investor, Mesoblast presents a compelling opportunity due to its low Forward PEG ratio of 0.53, indicating potential undervaluation relative to growth. The manageable Debt/Equity ratio of 0.22 suggests financial prudence, while the high gross profit margin of 78.3% reflects strong pricing power. Despite a low Piotroski F-Score, the company's ability to maintain a solid current ratio of 2.43 showcases liquidity strength, providing a cushion for future growth investments.

The Bear Case

The bear case for Mesoblast is glaring. The negative Price/Earnings and Price to FCF ratios underscore a company struggling with profitability and cash flow generation. With a Price/Sales ratio of 16.09, the stock appears overvalued relative to its revenue, and the operating margin of -96.11% signals severe inefficiencies. The stock's proximity to its 52-week high further suggests technical overextension, making it a risky bet for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$39.00

Institutional Ownership %

1-Year Beta

0.81

Insider Buying % (6 Mo)

Distance to 52-Week High

64.12%

Distance to 52-Week Low

9.24%

EARNINGS SURPRISE %

-23.22%

50-DAY SMA

$14.40

200-DAY SMA

$15.23

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.